|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM364428708 |
| 003 |
DE-627 |
| 005 |
20250305104642.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202307193
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1214.xml
|
| 035 |
|
|
|a (DE-627)NLM364428708
|
| 035 |
|
|
|a (NLM)37951210
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Wang, Zhenyu
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Laser-Activatable In Situ Vaccine Enhances Cancer-Immunity Cycle
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 28.12.2023
|
| 500 |
|
|
|a Date Revised 06.01.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 Wiley-VCH GmbH.
|
| 520 |
|
|
|a The immune response in cancer reflects a series of carefully regulated events; however, current tumor immunotherapies typically address a single key aspect to enhance anti-tumor immunity. In the present study, a nanoplatform (Fe3 O4 IR820@CpG)-based immunotherapy strategy that targets the multiple key steps in cancer-immunity cycle is developed: 1) promotes the release of tumor-derived proteins (TDPs), including tumor-associated antigens and pro-immunostimulatory factors), in addition to the direct killing effect, by photothermal (PTT) and photodynamic therapy (PDT); 2) captures the released TDPs and delivers them, together with CpG (a Toll-like receptor 9 agonist) to antigen-presenting cells (APCs) to promote antigen presentation and T cell activation; 3) enhances the tumor-killing ability of T cells by combining with anti-programmed death ligand 1 antibody (α-PD-L1), which collectively advances the outstanding of the anti-tumor effects on colorectal, liver and breast cancers. The broad-spectrum anti-tumor activity of Fe3 O4 @IR820@CpG with α-PD-L1 demonstrates that optimally manipulating anti-cancer immunity not singly but as a group provides promising clinical strategies
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a caner-immunity cycle
|
| 650 |
|
4 |
|a immunotherapies
|
| 650 |
|
4 |
|a in situ vaccine
|
| 650 |
|
4 |
|a photodynamic therapy
|
| 650 |
|
4 |
|a photothermal therapy
|
| 650 |
|
7 |
|a B7-H1 Antigen
|2 NLM
|
| 650 |
|
7 |
|a Vaccines
|2 NLM
|
| 700 |
1 |
|
|a You, Tingting
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Su, Qianyi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Deng, Wenjia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, JiaBao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hu, Saixiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shi, Shengjun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zou, Zhaowei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xiao, Jisheng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Duan, Xiaopin
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 35(2023), 52 vom: 10. Dez., Seite e2307193
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g volume:35
|g year:2023
|g number:52
|g day:10
|g month:12
|g pages:e2307193
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202307193
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 35
|j 2023
|e 52
|b 10
|c 12
|h e2307193
|